Double-blind study of Gabapentin in the treatment of partial seizures

Epilepsia. Jul-Aug 1991;32(4):539-42. doi: 10.1111/j.1528-1157.1991.tb04689.x.

Abstract

Forty-three patients completed a double-blind, placebo-controlled study of Gabapentin (GBP) as add-on therapy in partial and secondarily generalized seizures. All patients were followed for an initial 3-month baseline period, after which they were randomly allocated to receive either a placebo or 900 or 1,200 mg/day GBP for 3 months. A statistically significant difference in seizure frequency from the baseline to the treatment phase was noted between patients receiving placebo and GBP 1,200 mg, in whom seizure frequency decreased 57%. The GBP dosage of 900 mg appeared to be ineffective. A close relationship was observed between the serum GBP concentrations and the GBP dosage based on the seizure frequency. Serum GBP concentrations greater than 2 micrograms/ml resulted in a lower frequency of seizures. The adverse effects were minor and consisted mainly of transient drowsiness. GBP appears to be effective in the treatment of partial epileptic seizures in a dosage-related manner.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Acetates / administration & dosage
  • Acetates / adverse effects
  • Acetates / therapeutic use*
  • Adolescent
  • Adult
  • Amines*
  • Cyclohexanecarboxylic Acids*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Electroencephalography
  • Epilepsies, Partial / drug therapy*
  • Epilepsies, Partial / physiopathology
  • Female
  • Follow-Up Studies
  • Gabapentin
  • Headache / chemically induced
  • Humans
  • Male
  • Middle Aged
  • Placebos
  • Sleep Stages
  • gamma-Aminobutyric Acid*

Substances

  • Acetates
  • Amines
  • Cyclohexanecarboxylic Acids
  • Placebos
  • gamma-Aminobutyric Acid
  • Gabapentin